menu
    • menu

    Company profile for Chiesi Global Rare Diseases

    NEW Drugs in Dev: 5
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We understand that what matters most is you. Whether you’re an individual affected by rare disease, caregiver, doctor, or business partner, you drive us to build a better world. A world in which everyone can find the treatment and care we need. That’s why, after 85 years of experience, Chiesi Group launched Chiesi Global Rare Diseases in 2020.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Chiesi Global Rare DiseasesItaly Flag
    Country
    Country
    Italy
    Address
    Address
    Via Palermo, 26 A (ingresso Via G. Chiesi 1) 43122 Parma
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://chiesirarediseases.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Chiesi Global Rare Diseases Strengthens Rare Disease Community
    Chiesi Global Rare Diseases Strengthens Rare Disease Community

    06 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-06/chiesi-global-rare-diseases-reinforces-long-term-commitment-to-the-rare-disease-community-with-multiple-abstract-presentations-at-the-22nd-annual-worl

    PHARMIWEB
    06 Feb 2026
    Share Share
    Chiesi Global Rare Diseases Strengthens Rare Disease Community
    Chiesi Global Rare Diseases Strengthens Rare Disease Community

    05 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/05/3232947/0/en/Chiesi-Global-Rare-Diseases-Reinforces-Long-Term-Commitment-to-the-Rare-Disease-Community-with-Multiple-Abstract-Presentations-at-the-22nd-Annual-WORLDSymposium.html

    GLOBENEWSWIRE
    05 Feb 2026
    Share Share
    Chiesi, Protalix Get CHMP Nod For Elfabrio 4-Week Dosing In EU
    Chiesi, Protalix Get CHMP Nod For Elfabrio 4-Week Dosing In EU

    30 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/30/3229591/0/en/Chiesi-Global-Rare-Diseases-and-Protalix-BioTherapeutics-Receive-Positive-CHMP-Opinion-for-an-Additional-Dosing-Regimen-of-Every-Four-Weeks-for-Elfabrio-pegunigalsidase-alfa-in-the.html

    GLOBENEWSWIRE
    30 Jan 2026
    Share Share
    Chiesi Global Rare Diseases Receives Canada Approval of Elfabrio
    Chiesi Global Rare Diseases Receives Canada Approval of Elfabrio

    16 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/16/3206235/0/en/Chiesi-Global-Rare-Diseases-Announces-Health-Canada-Approval-of-Elfabrio-pegunigalsidase-alfa-for-Fabry-Disease.html

    GLOBENEWSWIRE
    16 Dec 2025
    Share Share
    Chiesi, Protalix Seek EMA Re-Exam for Elfabrio 4-Week Dosing
    Chiesi, Protalix Seek EMA Re-Exam for Elfabrio 4-Week Dosing

    03 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/03/3179856/0/en/Chiesi-Global-Rare-Diseases-and-Protalix-BioTherapeutics-Seek-Re-examination-from-the-EMA-for-the-Negative-Opinion-for-Elfabrio-pegunigalsidase-alfa-Alternative-Dosing-Regimen-of-E.html

    GLOBENEWSWIRE
    03 Nov 2025
    Share Share
    Chiesi, Protalix Get CHMP Negative View on Elfabrio Dose
    Chiesi, Protalix Get CHMP Negative View on Elfabrio Dose

    17 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/17/3168523/0/en/Chiesi-Global-Rare-Diseases-and-Protalix-Biotherapeutics-Acknowledge-CHMP-Negative-Opinion-on-Every-Four-Week-Dosing-Regimen-of-Elfabrio-pegunigalsidase-alfa-in-the-EU.html

    GLOBENEWSWIRE
    17 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search